This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fuller, K. Articles by Chambers, T. J. Search for Related Content PubMed PubMed Citation Articles by Fuller, K. Articles by Chambers, T. J.

TNF Potently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL

Department of Cellular Pathology, St. George’s Hospital Medical School, London SW17 ORE, United Kingdom

Address all correspondence and requests for reprints to: T. J. Chambers, Department of Cellular Pathology, St George’s Hospital Medical School, Cranmer Terrace, London SW17 0RE, United Kingdom. E-mail: . t.chambers{at}sghms.ac.uk

TNF is pivotal to the pathogenesis of inflammatory and possibly postmenopausal osteolysis. Much recent work has clarified mechanisms by which TNF promotes osteoclastogenesis, but the means by which it activates osteoclasts to resorb bone remain uncertain. We found that very low concentrations of TNF promoted actin ring formation, which correlates with functional activation in osteoclasts, both in osteoclasts formed in vitro and extracted from newborn rats. TNF was equipotent with RANKL for this action. Activation by TNF was unaffected by blockade of RANKL by OPG, its soluble decoy receptor, suggesting that this was due to a direct action on osteoclasts. Bone resorption was similarly directly and potently stimulated, in a RANKL-independent manner in osteoclasts, whether these were formed in vitro or in vivo. Interestingly, TNF promoted actin ring formation at concentrations an order of magnitude below those required for osteoclastic differentiation. Moreover, TNF strongly synergized with RANKL, such that miniscule concentrations of TNF were sufficient to substantially augment osteoclast activation. The extreme sensitivity of osteoclasts to activation by TNF suggests that the most sensitive osteolytic response of bone to TNF is through activation of existing osteoclasts; and the strong synergy with RANKL provides a mechanism whereby increased osteolysis can be achieved without disturbance to the underlying pattern of osteoclastic localization.

This article has been cited by other articles:

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				L. Duplomb, M. Dagouassat, P. Jourdon, and D. Heymann Concise Review: Embryonic Stem Cells: A New Tool to Study Osteoblast and Osteoclast Differentiation Stem Cells, March 1, 2007; 25(3): 544 - 552. [Abstract] [Full Text] [PDF]

				S. L. Teitelbaum Osteoclasts: What Do They Do and How Do They Do It? Am. J. Pathol., February 1, 2007; 170(2): 427 - 435. [Abstract] [Full Text] [PDF]

				A. R. Pettit, N. C. Walsh, C. Manning, S. R. Goldring, and E. M. Gravallese RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis Rheumatology, September 1, 2006; 45(9): 1068 - 1076. [Abstract] [Full Text] [PDF]

				B. Nardelli, L. Zaritskaya, W. McAuliffe, Y. Ni, C. Lincoln, Y. H. Cho, C. E. Birse, W. Halpern, S. Ullrich, and P. A. Moore Osteostat/Tumor Necrosis Factor Superfamily 18 Inhibits Osteoclastogenesis and Is Selectively Expressed by Vascular Endothelial Cells Endocrinology, January 1, 2006; 147(1): 70 - 78. [Abstract] [Full Text] [PDF]

				M. S. Bendre, A. G. Margulies, B. Walser, N. S. Akel, S. Bhattacharrya, R. A. Skinner, F. Swain, V. Ramani, K. S. Mohammad, L. L. Wessner, et al. Tumor-Derived Interleukin-8 Stimulates Osteolysis Independent of the Receptor Activator of Nuclear Factor-{kappa}B Ligand Pathway Cancer Res., December 1, 2005; 65(23): 11001 - 11009. [Abstract] [Full Text] [PDF]

				J. G. Conway, B. McDonald, J. Parham, B. Keith, D. W. Rusnak, E. Shaw, M. Jansen, P. Lin, A. Payne, R. M. Crosby, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580 PNAS, November 1, 2005; 102(44): 16078 - 16083. [Abstract] [Full Text] [PDF]

				N. Kim, Y. Kadono, M. Takami, J. Lee, S.-H. Lee, F. Okada, J. H. Kim, T. Kobayashi, P. R. Odgren, H. Nakano, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis J. Exp. Med., September 6, 2005; 202(5): 589 - 595. [Abstract] [Full Text] [PDF]

				S. D. Yogesha, S. M. Khapli, and M. R. Wani Interleukin-3 and Granulocyte-Macrophage Colony-stimulating Factor Inhibits Tumor Necrosis Factor (TNF)-{alpha}-induced Osteoclast Differentiation by Down-regulation of Expression of TNF Receptors 1 and 2 J. Biol. Chem., March 25, 2005; 280(12): 11759 - 11769. [Abstract] [Full Text] [PDF]

				J. M. Lean, C. J. Jagger, B. Kirstein, K. Fuller, and T. J. Chambers Hydrogen Peroxide Is Essential for Estrogen-Deficiency Bone Loss and Osteoclast Formation Endocrinology, February 1, 2005; 146(2): 728 - 735. [Abstract] [Full Text] [PDF]

				C. J. Jagger, J. M. Lean, J. T. Davies, and T. J. Chambers Tumor Necrosis Factor-{alpha} Mediates Osteopenia Caused by Depletion of Antioxidants Endocrinology, January 1, 2005; 146(1): 113 - 118. [Abstract] [Full Text] [PDF]

				Y. Takada and B. B. Aggarwal Evidence that genetic deletion of the TNF receptor p60 or p80 in macrophages modulates RANKL-induced signaling Blood, December 15, 2004; 104(13): 4113 - 4121. [Abstract] [Full Text] [PDF]

				S. Colucci, G. Brunetti, R. Rizzi, A. Zonno, G. Mori, G. Colaianni, D. Del Prete, R. Faccio, A. Liso, S. Capalbo, et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction Blood, December 1, 2004; 104(12): 3722 - 3730. [Abstract] [Full Text] [PDF]

				D O' Gradaigh, D Ireland, S Bord, and J E Compston Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor {alpha}, interleukin 1, and receptor activator of nuclear factor {kappa}B ligand (RANKL) regulate osteoclasts Ann Rheum Dis, April 1, 2004; 63(4): 354 - 359. [Abstract] [Full Text] [PDF]

				D. O'Gradaigh and J. E. Compston T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion Rheumatology, February 1, 2004; 43(2): 122 - 130. [Full Text] [PDF]

				E. Grimaud, L. Soubigou, S. Couillaud, P. Coipeau, A. Moreau, N. Passuti, F. Gouin, F. Redini, and D. Heymann Receptor Activator of Nuclear Factor {kappa}B Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis Am. J. Pathol., November 1, 2003; 163(5): 2021 - 2031. [Abstract] [Full Text] [PDF]

				T. M. Doherty, K. Asotra, L. A. Fitzpatrick, J.-H. Qiao, D. J. Wilkin, R. C. Detrano, C. R. Dunstan, P. K. Shah, and T. B. Rajavashisth Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads PNAS, September 30, 2003; 100(20): 11201 - 11206. [Abstract] [Full Text] [PDF]

				S. M. Khapli, L. S. Mangashetti, S. D. Yogesha, and M. R. Wani IL-3 Acts Directly on Osteoclast Precursors and Irreversibly Inhibits Receptor Activator of NF-{kappa}B Ligand-Induced Osteoclast Differentiation by Diverting the Cells to Macrophage Lineage J. Immunol., July 1, 2003; 171(1): 142 - 151. [Abstract] [Full Text] [PDF]

				G. Toraldo, C. Roggia, W.-P. Qian, R. Pacifici, and M. N. Weitzmann IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells PNAS, January 7, 2003; 100(1): 125 - 130. [Abstract] [Full Text] [PDF]